	US 12,290,528 B2
	Compositions and methods for treatment of sepsis-related disorders
John Mansell, Gillette, WY (US)
Filed by John Mansell, Gillette, WY (US)
Filed on Apr. 19, 2023, as Appl. No. 18/302,841.
Application 18/302,841 is a continuation of application No. 16/647,853, granted, now 11,642,365, previously published as PCT/US2018/052050, filed on Sep. 20, 2018.
Claims priority of provisional application 62/562,060, filed on Sep. 22, 2017.
Prior Publication US 2023/0285440 A1, Sep. 14, 2023
Int. Cl. C07H 21/02 (2006.01); A61K 31/713 (2006.01); A61K 38/00 (2006.01); A61P 31/00 (2006.01); C12N 15/113 (2010.01)

CPC A61K 31/713 (2013.01) [A61K 38/005 (2013.01); A61P 31/00 (2018.01); C12N 15/1137 (2013.01); C12N 2310/14 (2013.01); C12Y 114/13039 (2013.01); C12Y 304/24086 (2013.01)]

7 Claims

1. A method comprising administering an oligonucleotide effective to disrupt one or more pathways leading to sepsis to a subject, wherein the oligonucleotide is an α disintegrin and metalloproteinase (ADAMD) enzyme inhibitor, wherein the ADAM enzyme inhibitor is effective to decrease the expression of ADAM enzyme by at least 50%, wherein the ADAM enzyme inhibitor has a length of twenty-one nucleotides, and wherein the ADAM enzyme inhibitor comprises a polynucleotide strand exhibiting at least 70% sequence identity to one of Sequence ID No. 49 through Sequence ID No. 56.